What Happened?
Shares of pharmaceutical company AbbVie (NYSE:ABBV) jumped 3.5% in the afternoon session after the company reported first-quarter results that featured a revenue beat.
The company announced revenue of $15 billion, surpassing Wall Street's expectation of $14.75 billion, driven by high demand for its newer immunology drugs, Skyrizi and Rinvoq. However, its adjusted earnings of $2.65 per share fell just short of the $2.67 consensus estimate.
Looking ahead, AbbVie lowered its full-year 2026 adjusted earnings guidance to $14.18 at the midpoint, representing a 2% decrease. Investors appeared to focus on the strong revenue performance, which overshadowed the earnings miss and the more cautious outlook for the rest of the year.
After the initial pop the shares cooled down to $204.66, up 3.5% from previous close.
Is now the time to buy AbbVie? Access our full analysis report here, it’s free.
What Is The Market Telling Us
AbbVie’s shares are not very volatile and have only had 3 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The previous big move we wrote about was 27 days ago when the stock dropped 3% on the news that reports revealed that the US may impose up to 100% tariffs on imports of branded and patented drugs.
This potential move would target pharmaceutical companies that have not negotiated deals to lower drug prices in the United States. The news sparked a significant sell-off in the sector, with the Nifty Pharma index declining over 5% as all its constituent stocks traded lower. The concerns were particularly pronounced for international drugmakers who rely on the US market.
AbbVie is down 10.8% since the beginning of the year, and at $204.66 per share, it is trading 16.3% below its 52-week high of $244.38 from September 2025. Despite the year-to-date decline, investors who bought $1,000 worth of AbbVie’s shares 5 years ago would now be looking at an investment worth $1,846.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.